This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. Abstract Background/Aims: Promyelocytic leukemia (PML) protein is a tumor suppressor that fuses with retinoic acid receptor-α (PML-RARα) to contribute to the initiation of acute promyelocytic leukemia (APL). Arsenic trioxide (ATO) upregulates expression of TGF-β1, promoting collagen synthesis in osteoblasts, and ATO binds directly to PML to induce oligomerization, sumoylation, and ubiquitination. However, how ATO upregulates TGF-β1 expression is uncertain. Thus, we suggested that PML sumoylation is responsible for regulation of TGF-β1 protein expression. Methods: Kunming mice were treated with ATO, and osteoblasts were counted under scanning electron microscopy. Masson's staining was used to quantify collagen content. hFOB1.19 cells were transfected with siRNA against UBC9 or RNF4, and then treated with ATO or FBS. TGF-β1, PML expression, and sumoylation were quantified with Western blot, and collagen quantified via immunocytochemistry. Results: ATO enhanced osteoblast accumulation, collagen synthesis, and PML-NB formation in vivo. Knocking down UBC9 in hFOB1.19 cells inhibited ATO-and FBS-induced PML sumoylation, TGF-β1 expression, and collagen synthesis. Conversely, knocking down RNF4 enhanced ATO-and FBS-induced PML sumoylation, TGF-β1 expression, and collagen synthesis. Conclusion: These data suggest that PML sumoylation is required for ATO-induced collagen synthesis in osteoblasts.
Introduction
Promyelocytic leukemia (PML) is a tumor suppressor protein that was first recognized as part of a fusion protein with retinoic acid receptor-α (PML-RARα). This fusion protein Xu et 
Cell culture
The human osteoblast hFOB1.19 cell line was purchased from the Chinese Academy of Sciences (Shanghai, China), and cells were cultured in complete culture medium containing 0.3 mg/ml G418 in F12 medium with 10% FBS at 34°C under 5% CO 2 . Any non-adherent cells were removed with media changes and adherent cells were retained in the culture dish for further growth. Media were changed every 3 days, as described previously [21] .
Western blotting hFOB1.19 cells were lysed in SDS buffer containing protease inhibitors (Huatesheng Biotechnology, Fushun, China) and isolated proteins were separated by SDS-PAGE and electro-transferred to nitrocellulose membranes which were incubated overnignt at 4°C with the following primary antibody dilutions: PML (Santa Cruz, CA), SUMO1 (Santa Cruz), SUMO2/3 (Invitrogen, Carlsbad, CA), TGF-β1 (Abcam, Shanghai, China), UBC9 (Cell Signaling Technologies, Danvers, MA), RNF4 (Cell Signaling), β-actin (Research Diagnostics Inc., Flanders, NJ), and Gap (Research Diagnostics). After washing, membranes were incubated with the appropriate secondary antibodies (goat anti-rabbit and -mouse IgG; Abcam). Protein expression was quantified using Odyssey V3.0 software (LI-COR, Lincoln, NE).
Immunofluorescent staining
hFOB1.19 cells were cultured in six-well plates on glass cover slips and transfected with expression plasmids (GenePharma, Suzhou, China) using Lipofectamine 2000 (Invitrogen, Beijing, China) according to the manufacturer's instructions. Six hours after transfection the culture media were switched to media containing 10% FBS but lacking penicillin-streptomycin, and cells were cultured for an additional 12 h. Cells were fixed 15 min after transfection using 4% paraformaldehyde in PBS for 20 min, and permeabilized using 0.5% Triton X-100 in PBS for 10 min. They were then blocked using 4% BSA in PBS for 20 min prior to incubation with mouse anti-PML antibodies (Santa Cruz) and Alexa 488-conjugated secondary antibodies (Invitrogen). Stained cells were mounted onto glass slides using Shandon Immu-Mount (Thermo Fisher Scientific, location) containing DAPI to visualize cell nuclei. Confocal laser microscopy was performed using an Olympus microscope (Tokyo, Japan) and the presence of PML-NBs was determined using Fluoview software v.5.0 (Olympus).
Collagen measurement hFOB1.19 cells were cultured in six-well plates and transfected as described above. Total collagen content was determined by using a Sircol™ Collagen Assay kit (Biocolor Ltd., Northern Ireland) as described previously [21, 22] . Briefly, 0.05 M Tris buffer (pH 7.5) was used to lyse cells, and 1 mL of Sircol Dye reagent was used to stain the lysate (100 mL).Contents were mixed for 30 min and centrifuged for 10 min (at >10,000 × g) to pellet the bound dye. Each tube received 1 mL of the alkali reagent to dissolve the bound dye, and the absorbance value was read at 540 nm. Collagen content (mg) was converted to protein units using the linear calibration curve generated from standards (Vitrogen 100; Angiotech Biomaterials, Palo Alto, CA, USA) and was normalized to the total protein (mg) of each sample.
Animals
Mice were obtained from the Experimental Animal Center of Harbin Medical University (Grade II). Food and water were available freely throughout all experiments. Male Kunming mice weighting 20-25 g were divided randomly into three groups (n = 6/group): controls, experimental animals treated with 1 mg/ 
Histological analyses and electron microscopy
Femurs were harvested from all mice at the end of the experiment (at 1 and 2 weeks) and bone crosssections were fixed in 4% formalin and decalcified by incubation in EDTA-2Na for 2 weeks. Hematoxylin and eosin (H&E) staining was applied to visualize osteoblasts as reported previously [25] , and Masson's staining with transmission electron microscopy (TEM) was used to quantify collagen using routine methods [26] . Finally, scanning electron microscopy (SEM) was used to assess osteoblast differentiation.
Statistical analysis
Data are presented as means ± standard deviations (SDs). Differences between groups were evaluated using Student's t-tests, and P < 0.05 was used to define statistically significant differences. Statistical analyses were performed using GraphPad Prism 5 software (La Jolla, CA).
Results

ATO promotes collagen synthesis and stimulates PML-NB formation in bone tissue
To assess the effects of ATO on bone histology, collagen synthesis, and PML sumoylation in vivo, Kunming mice femurs were harvested and analyzed using Masson's staining and EM. Figure 1A shows that control femurs had little collagen accumulation, and that most osteoblasts were pre-osteoblasts (left panels). However, ATO increased collagen accumulation significantly in a time-dependent manner, as indicated by increased staining sections in mice treated for 1 and 2 weeks (Fig. 1A upper panels and 1B; P < 0.05). Furthermore, ATO increased osteoblast formation in a time-dependent manner. After 1-week treatment, occasional bone cells were observed and the endoplasmic reticulum was developed. These effects were greater in mice that received ATO for 2 weeks, in which osteocytes covered most of the surface of the trabecular bone ( Fig. 1A; lower panel) .
Because studies suggest that PML protein and nuclear bodies (PML-NBs) formation play instrumental roles in tumor suppression [27, 28] and that ATO treatment leads to PML degradation and enhances PML-NBs formation [29, 30] , we performed immunohistochemical staining for PML in control and ATO-treated mice (Fig. 1C) . Data show that ATO increased PML-NBs formation slightly after both 1 and 2 weeks.
ATO and FBS induce PML sumoylation and PML-NB formation
Because previous data revealed that ATO stimulated PML sumoylation and subsequent degradation [29, 31] , we measured PML sumoylation in hFOB1.19 human osteoblasts. Data revealed that expression of high molecular weight forms of PML (>110 kDa) increased in parallel with SUMO-1 and SUMO-2/3 as cells were incubated with ATO and FBS over time. Thus, ATO increased PML sumoylation, consistent with previous reports [32, 33] .
Data to assess the effects of ATO on PML-NBs formation in hFOB1.19 cells (Fig. 2C ), show that both FBS and ATO increased PML-NBs formation compared with control cells; however, ATO had a greater effect.
Knocking down UBC9 prevents ATO-and FBS-induced PML sumoylation
Because UBC9 is a SUMO-conjugating enzyme [34] , we investigated its role in ATOand FBS-induced PML sumoylation. Western blot confirmed that UBC9 expression was reduced significantly (~60%) compared with untransfected (ctl) and NC-transfected cells ( Fig. 3A ; P < 0.05). Transfecting hFOB1.19 cells with si-UBC9 alone had no effect on PML expression or sumoylation (Fig. 3B) . As expected, treatment with ATO for 4 h increased PML expression and sumoylation in control and NC-transfected cells (Fig. 3B) . However, these 
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Cellular Physiology and Biochemistry effects were reduced in cells transfected with si-UBC9. Similar effects were observed in FBStreated hFOB1.19 cells (Fig. 3D) . Specifically, FBS treatment increased PML expression and sumoylation, and these effects were reduced in cells that had been pre-transfected with si-UBC9. Transfection studies with si-UBC9 alone had no effect on PML-NBs formation, as expected ( Fig. 3C and 3E ). However, transfection with si-UBC9 but not NC inhibited both ATO- (Fig. 3C ) and FBS-induced (Fig. 3E ) PML-NBs formation.
Knocking down UBC9 reduced ATO-and FBS-induced TGF-β1 expression and collagen synthesis
ATO is reported to upregulate TGF-β1 expression [21, 22] and UBC9 is thought to regulate TGF-β expression and signaling [35] . So we used transfection studies to assess scrambled control (NC)-or UBC9-siRNA treated with ATO (Fig. 4A) or FBS (Fig. 4B) . TGF-β1 was measured and we concluded that transfection with si-UBC9 had no effect on TGF-β1 expression. Also, ATO and FBS both increased TGF-β1 expression significantly compared with control cells (P < 0.05); however, both ATO-and FBS-induced TGF-β1 expression was inhibited be pre-transfection with si-UBC9 (Fig. 4A, B) .
To learn whether UBC9 was important for ATO-and FBS-induced collagen synthesis in cultured osteoblasts, hFOB1.19 cells were treated with either FBS or ATO and relative collagen content increased significantly compared with control cells (both P < 0.05). These effects were inhibited significantly by pre-transfection with si-UBC9. , and PML-NBs formation was measured immunofluorescently (green); sections were counterstained with DAPI (blue) to visualize the cell nuclei (C, E), n = 3.
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Knocking down RNF4 promotes ATO-and FBS-induced PML sumoylation
RNF4 is an E3 ubiquitin ligase that ubiquitinates sumoylated PML in PML-NBs [12] ro we investigated its role in ATO-induced PML sumoylation. After knockdown of RNF4 with specific siRNA (si-RNF4), hFOB1.19 cells were transfected with scrambled control (NC)-or RNF4-siRNA, and Western blot confirmed that RNF4 expression was reduced significantly (~30%) compared with untransfected (ctl) and NC-transfected cells ( Fig. 5A ; P < 0.05).
Also, transfecting hFOB1.19 cells with si-RNF4 alone had no effect on PML expression or sumoylation ( Fig. 5B and 3D ) and treatment with ATO increased expression and sumoylation of PML compared with control and NC-transfected cells (Fig. 5B) . However, pre-transfection with si-RNF4 increased ATO-induced PML expression and sumoylation. Similar effects were observed in FBS-treated hFOB1.19 cells (Fig. 5D) . Briefly, FBS treatment increased PML expression and sumoylation, which was enhanced by pre-transfection with si-RNF4.
Studies to understand whether RNF4 is important in ATO-and FBS-induced PMLNBs formation revealed that transfection with si-RNF4 alone had no effect on PML-NBs formation, (Fig. 5C and 3E) . However, transfection with si-RNF4 but not NC enhanced both ATO- (Fig. 5C ) and FBS-induced (Fig. 5E ) PML-NBs formation. Thus, RNF4 inhibits ATO-and FBS-induced PML sumoylation and PML-NBs formation.
Knocking down RNF4 enhances ATO-and FBS-induced TGF-β1 expression and collagen synthesis
Finally, we investigated whether RNF4 plays a role in ATO-induced upregulation of TGF-β1. hFOB1.19 cells transfected with scrambled control (NC)-or RNF4-siRNA and then treated with ATO (Fig. 6A) or FBS (Fig. 6B) were assayed for TGF-β1. As expected, transfection with si-RNF4 alone did not change TGF-β1 expression and ATO and FBS both increased TGF-β1 expression significantly compared with control cells (P < 0.05). However, both ATO-and FBS-induced TGF-β1 expression was inhibited by pre-transfection with si-RNF4 ( Fig. 6A and 6B) .
Finally, (Fig. 6C) we treated hFOB1.19 cells with either FBS or ATO and noted increased relative collagen content of cells compared with control cells (both P < 0.05). Interestingly, si-RNF4 transfection enhanced ATO-induced TGF-β synthesis after 4 h, but not 24 h and si-RNF4 increased FBS-induced TGF-β1 synthesis. 
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Discussion
Our work confirms that ATO enhanced osteoblast accumulation, and increased collagen synthesis and PML-NBs formation in vivo and in vitro. Knocking down SUMO-conjugating enzyme UBC9 with specific siRNA inhibited ATO-and FBS-induced PML sumoylation and TGF-β1 expression. Furthermore, knocking down RNF4, the poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation using siRNA enhanced ATO-and FBSinduced PML sumoylation and TGF-β1 expression. In addition, increased PML-NBs formation for serum response was verified [36] . Therefore, we assessed whether osteoblasts can affect the formation of PML-NBs. In hFOB1.19 cells, serum can increase the formation of PML-NBs after sumoylation.
The PML-RARα fusion protein is found in approximately 98% of patients with APL [37] , so many APL treatments are designed to disrupt or inhibit PML-RARα downstream signaling [1] . A major treatment modality is all-trans retinoic acid (ATRA) therapy, which is a natural ligand for RARs. ATRA therapy functions by destroying PML-RARα, which eradicates or induces the terminal differentiation of leukemia-initiating cells (LICs). This induces the complete remission in almost all PML-RARα-positive APL patients [36, 38] . However, for patients the ATRA binding site in PML-RARα becomes mutated, reducing the sensitivity of LICs to ATRA-induced terminal differentiation and causes relapse. Thus, additional treatments are needed [39] . . PML-NBs formation was measured immunofluorescently (green); sections were counterstained with DAPI (blue) to visualize cell nuclei (C, E), n = 3.
